JP2001513504A5 - - Google Patents

Download PDF

Info

Publication number
JP2001513504A5
JP2001513504A5 JP2000506973A JP2000506973A JP2001513504A5 JP 2001513504 A5 JP2001513504 A5 JP 2001513504A5 JP 2000506973 A JP2000506973 A JP 2000506973A JP 2000506973 A JP2000506973 A JP 2000506973A JP 2001513504 A5 JP2001513504 A5 JP 2001513504A5
Authority
JP
Japan
Prior art keywords
carrier
group
pharmaceutically acceptable
pharmaceutical composition
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2000506973A
Other languages
English (en)
Japanese (ja)
Other versions
JP2001513504A (ja
JP4335435B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CA1998/000744 external-priority patent/WO1999007383A1/en
Publication of JP2001513504A publication Critical patent/JP2001513504A/ja
Publication of JP2001513504A5 publication Critical patent/JP2001513504A5/ja
Application granted granted Critical
Publication of JP4335435B2 publication Critical patent/JP4335435B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2000506973A 1997-08-05 1998-08-05 細胞増殖および細胞死を調節する組成物および方法 Expired - Fee Related JP4335435B2 (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US5477797P 1997-08-05 1997-08-05
US60/054,777 1997-08-05
US7506798P 1998-02-18 1998-02-18
US7511198P 1998-02-18 1998-02-18
US60/075,111 1998-02-18
US60/075,067 1998-02-18
US8631798P 1998-05-21 1998-05-21
US60/086,317 1998-05-21
PCT/CA1998/000744 WO1999007383A1 (en) 1997-08-05 1998-08-05 Composition and method for regulating cell proliferation and cell death

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2008124958A Division JP2008208140A (ja) 1997-08-05 2008-05-12 細胞増殖および細胞死を調節する組成物および方法

Publications (3)

Publication Number Publication Date
JP2001513504A JP2001513504A (ja) 2001-09-04
JP2001513504A5 true JP2001513504A5 (enExample) 2008-08-21
JP4335435B2 JP4335435B2 (ja) 2009-09-30

Family

ID=27489673

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2000506973A Expired - Fee Related JP4335435B2 (ja) 1997-08-05 1998-08-05 細胞増殖および細胞死を調節する組成物および方法
JP2008124958A Withdrawn JP2008208140A (ja) 1997-08-05 2008-05-12 細胞増殖および細胞死を調節する組成物および方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2008124958A Withdrawn JP2008208140A (ja) 1997-08-05 2008-05-12 細胞増殖および細胞死を調節する組成物および方法

Country Status (17)

Country Link
US (2) US6326357B1 (enExample)
EP (1) EP1003525B1 (enExample)
JP (2) JP4335435B2 (enExample)
KR (1) KR100533576B1 (enExample)
AT (1) ATE227996T1 (enExample)
AU (1) AU736450B2 (enExample)
BR (1) BR9815602A (enExample)
CA (1) CA2299548C (enExample)
DE (1) DE69809561T2 (enExample)
DK (1) DK1003525T3 (enExample)
ES (1) ES2187047T3 (enExample)
HU (1) HU227921B1 (enExample)
IL (3) IL134371A0 (enExample)
NO (1) NO322450B1 (enExample)
NZ (1) NZ502674A (enExample)
PT (1) PT1003525E (enExample)
WO (1) WO1999007383A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1003525E (pt) 1997-08-05 2003-03-31 Bioniche Life Sciences Inc Composicao e metodo para a regulacao da proliferacao e da morte celular
DE69829316T2 (de) * 1998-02-18 2006-04-13 Bioniche Life Sciences Inc., Belleville Behandlung des harnblasenkrebses durch mycobacterium phlei zellwand
DK1135161T3 (da) * 1998-12-04 2005-01-24 Bioniche Life Sciences Inc Kemoterapeutisk sammensætning og fremgangsmåde
WO2000033879A1 (en) * 1998-12-04 2000-06-15 Bioniche Life Sciences Inc. Method for the treatment of inflammation
US6809081B1 (en) * 1998-12-04 2004-10-26 Bioniche Life Sciences, Inc. Chemotherapeutic composition and method
PT1165106E (pt) * 1999-04-01 2005-10-31 Bioniche Life Sciences Inc Composicoes e metodo para induzir apoptose em celulas de cancro da prostata, por m-adn e mcc
US6794368B1 (en) 1999-04-01 2004-09-21 Bioniche Life Sciences Inc. Composition and method for inducing apoptosis in prostate cancer cells
US7314926B1 (en) 1999-04-08 2008-01-01 Antisoma Research Limited Antiproliferative activity of g-rich oligonucleotides and method of using same to bind to nucleolin
WO2001022979A1 (en) * 1999-09-29 2001-04-05 Bioniche Life Sciences Inc. Method to disrupt mitochondrial function
CZ20022372A3 (cs) * 1999-12-13 2002-11-13 Bioniche Life Sciences Inc. Terapeuticky pouľitelné syntetické oligonukleotidy
US7125858B2 (en) 1999-12-28 2006-10-24 Bioniche Life Sciences Inc. Hyaluronic acid in the treatment of cancer
US20030044352A1 (en) * 2001-04-24 2003-03-06 Phillips Nigel C. Method for evaluating the efficacy of treatment with bacterial DNA and bacterial cell walls
US6673566B1 (en) 2002-01-10 2004-01-06 The United States Of America As Represented By The Secretary Of Agriculture Diagnosis of pathogen infections through analysis of nitrite production by antigen stimulated leukocytes
JP2009544680A (ja) 2006-07-25 2009-12-17 リポクセン テクノロジーズ リミテッド ポリサッカライドによるタンパク質のｎ末端誘導体化
HUE052413T2 (hu) 2010-10-13 2021-04-28 Telesta Therapeutics Inc Bakteriális ribonukleinsav-sejtfalkészítmények és elõállítási és felhasználási módszereik

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3172815A (en) 1962-04-24 1965-03-09 Warner Lambert Pharmaceutical Method for preparing reticulo-endo-thelial system stimulant and stimulant thereof
US4152423A (en) 1971-11-19 1979-05-01 Agence Nationale De Valorisation De La Recherche (Anvar) Immunological agents
FR2160326B1 (enExample) 1971-11-19 1975-02-07 Anvar
CH602920A5 (enExample) 1973-02-23 1978-08-15 Wellcome Found
US3976544A (en) 1973-06-19 1976-08-24 The Agence Nationale De Valorisation De Le Recherche Water-soluble immunological adjuvants, in particular for vaccines, obtained from mycobacteria and related microorganisms and process for their extraction
FR2374042A1 (fr) 1976-06-04 1978-07-13 Merieux Inst Nouveau medicament immunostimulant et son procede de preparation
JPS54140710A (en) 1978-03-10 1979-11-01 Mitsui Toatsu Chem Inc Anti-tumor substance and its preparation
DE3011461C2 (de) 1980-03-25 1986-10-30 Dr. Madaus & Co, 5000 Köln Verwendung von Propionibakterien
US4520019A (en) 1982-04-29 1985-05-28 Ribi Immunochem Research, Inc. Stable composition and preparation thereof
US4579941A (en) 1982-08-13 1986-04-01 Mitsuitoatsu Chemicals, Inc. Thermally-denatured deoxyribonucleic acid MD-011 and antitumor agent
US4663306A (en) 1983-09-23 1987-05-05 Ribi Immunochem Research, Inc. Pyridine-soluble extract-refined detoxified endotoxin composition and use
GB8404280D0 (en) 1984-02-17 1984-03-21 Stanford J L Biological preparations
US4744984A (en) 1985-10-08 1988-05-17 Vetrepharm Research, Inc. Antiviral immunotherapeutic agent and preparation thereof
US4877611A (en) 1986-04-15 1989-10-31 Ribi Immunochem Research Inc. Vaccine containing tumor antigens and adjuvants
CN1102855C (zh) 1993-01-29 2003-03-12 维特里制药有限公司 免疫治疗组合物
PT1003525E (pt) 1997-08-05 2003-03-31 Bioniche Life Sciences Inc Composicao e metodo para a regulacao da proliferacao e da morte celular

Similar Documents

Publication Publication Date Title
JP2001513504A5 (enExample)
JP2000507362A5 (enExample)
DZ2887A1 (fr) Dérivés d'azétidine, leur préparation et les médicaments les contenant.
SG113402A1 (en) Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
HUP0000714A3 (en) New formulation for inhalation having a poured bulk density of 0.28 to 0.38 g/ml, a process for preparing the formulation and the use thereof
FR2805818B1 (fr) Derives d'azetidine, leur preparation et les compositions pharmaceutiques les contenant
ZA979220B (en) New oxadiazoles, processes for their preparation and their use as pharmaceutical compositions.
DE69928260D1 (de) Schwefel-substituierte sulfonylaminocarbonsäure n-arylamide, ihre herstellung, ihre anwendung und diese enthaltende pharmazeutische zusammensetzungen
CA2153856A1 (en) Duloxetine enteric pellets
USD438297S1 (en) Deodorizing apparatus for personal use
CA2232450A1 (en) Oral pharmaceutical composition containing antimicrobial actives and sustained release pantoprazole
HUP0101434A3 (en) Sulfonamide-containing indole compounds, use of them for producing pharmaceutical compositions and pharmaceutical compositions containing the same
JP2003520017A5 (enExample)
GB0117095D0 (en) "Process for the preparation of pure citalopram"
CA2163837A1 (en) Crystalline Paclitaxel Hydrates
HUP0200386A3 (en) Nitroxyderivatives having antiinflammatory, analgesic and antithrombotic activity and pharmaceutical compositions containing them and their use
PL366851A1 (en) Combined preparations, containing 1,4-benzothiepine-1,1-dioxide derivatives and other active substances, and the use thereof
IT1293281B1 (it) Metodo ed unita' per il trasferimento, con ribaltamento, di pacchetti di sigarette.
CA2256751A1 (fr) Comprime enrobe a base de maleate de trimebutine
WO2001035940A3 (en) Pharmaceutical composition comprising a thiazolidinedione-metformin hydrochloride
FR2703995B1 (fr) 5-acylamino 1,2,4-thiadiazoles, leur preparation et compositions pharmaceutiques en contenant.
USD435197S (en) Bowl
IT1286496B1 (it) Composizione farmaceutica orale ad attivita' antipiretica,analgesica ed antiinfiammatoria
PT1131297E (pt) Certas caprolactamas substituidas composicoes farmaceuticas contendo-as e sua utilizacao no tratamento de tumores
JPH10237071A5 (enExample)